S
Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ · Healthcare · 2.8B
Closing price
$42.67
+1.26% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
2.3×
Enterprise value / EBITDAEV/EBITDA
54.6×
Free cash flow yieldFCF yield
1.9%
Return on equityROE
-3.6%
Operating margin
-5.1%
Net debt / EBITDAbalance-sheet strength
-2.1×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.